Informace o publikaci

Side Effects of COVID-19 Vaccines Primer Doses: Experience of Saudi Healthcare Workers Participating in CoVaST-SA

Logo poskytovatele
Logo poskytovatele
Autoři

RIAD Abanoub ALSAAD S. S. ALMURIKHI A. A. ALZAHRANI F. A. ALGHAMDI A. M. ALZAID E. H. KLUGAR Miloslav

Rok publikování 2022
Druh Článek v odborném periodiku
Časopis / Zdroj Vaccines
Fakulta / Pracoviště MU

Lékařská fakulta

Citace
www https://www.mdpi.com/2076-393X/10/12/2137
Doi http://dx.doi.org/10.3390/vaccines10122137
Klíčová slova CoVaST; COVID-19 vaccines; drug-related side effects and adverse reactions; health personnel; Saudi Arabia
Přiložené soubory
Popis Background: Side effects emerging after COVID-19 vaccines may adversely impact public confidence in vaccines. Therefore, this study was designed to explore the short-term side effects of COVID-19 vaccines as a part of the COVID-19 Vaccines Safety Tracking (CoVaST) study. Methods: A cross-sectional survey-based study was carried out to collect data from healthcare workers (HCWs) in Saudi Arabia. The study was initiated between June and December 2021. A validated questionnaire was used in this study consisting of four categories, including demographic characteristics and medical anamnesis of the participants, COVID-19-associated anamnesis, and side effects of vaccine uptake. Results: The study included 1039 participants, of which 70.2% were females, and their median age was 34. About 82.9% and 52.3% of the participants reported a minimum of both one local and systemic side effect, respectively. Females, young participants (?34 years old), and non-obese participants had more potential to disclose post-vaccination side effects than their counterparts. Heterologous schedules and viral vector-based vaccines were linked with a greater rate of systemic side effects, whereas homologous vaccination schedules and mRNA-based vaccines were linked with a greater rate of local side effects. Conclusion: Future studies on COVID-19 vaccines should focus on the role of BMI, previous infection, and vaccination schedule in terms of vaccine safety and reactogenicity.
Související projekty:

Používáte starou verzi internetového prohlížeče. Doporučujeme aktualizovat Váš prohlížeč na nejnovější verzi.

Další info